Editorial comment on: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
Porru
Daniele
D
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D003408:Cresols / Q000627:therapeutic use*; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D018721:Muscarinic Agonists / Q000627:therapeutic use*; D009929:Organ Size / Q000187:drug effects; D010665:Phenylpropanolamine / Q000627:therapeutic use*; D011467:Prostate / Q000033:anatomy & histology* / Q000187:drug effects; D016032:Randomized Controlled Trials as Topic; D013449:Sulfonamides / Q000627:therapeutic use*; D000077409:Tamsulosin; D000068737:Tolterodine Tartrate; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D014551:Urinary Tract / Q000187:drug effects / Q000503:physiopathology*; D014554:Urination / Q000187:drug effects / Q000502:physiology
D000317:Adrenergic alpha-Antagonists; D001559:Benzhydryl Compounds; D003408:Cresols; D003692:Delayed-Action Preparations; D018721:Muscarinic Agonists; D013449:Sulfonamides; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; D000077409:Tamsulosin